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Abstract 
Background: Curcumin is one of the leading compound extracted from the dry powder of Curcuma longa (Zingib‑
eraceae family), which possess several pharmacological properties. However, in vivo administration exhibited limited 
applications in cancer therapies.
Results: Twenty‑four curcumin derivatives have synthesized, which comprises cyclohexanone 1–10, acetone 
11–17 and cyclopentanone 18–24 series. All the curcuminoids were synthesized by the acid or base catalyzed 
Claisen Schmidt condenstion reactions, in which β‑diketone moiety of curcumin was modified with mono‑ketone. 
These curcuminoids 1–24 were screened against HeLa, K562, MCF‑7 (an estrogen‑dependent) and MDA‑MB‑231 
(an estrogen‑independent) cancer cell lines. Among them, acetone series 11–17 were found to be more selective 
and potential cytotoxic agents. The compound 14 was exhibited  (IC50 = 3.02 ± 1.20 and 1.52 ± 0.60 µg/mL) against 
MCF‑7 and MDA‑MB‑231 breast cancer cell lines. Among the cyclohexanone series, the compound 4 exhibited 
 (IC50 = 11.04 ± 2.80, 6.50 ± 01.80, 8.70 ± 3.10 and 2.30 ± 1.60 µg/mL) potential cytotoxicity against four proposed 
cancer cell lines, respectively. All the curcucminoids were characterized with the detailed 1H NMR, IR, UV–Vis, and mass 
spectroscopic techniques. The structure of compound 4 was confirmed by using the single X‑ray crystallography. 
Additionally, we are going to report the first time spectral data of (2E,6E)‑2,6‑bis(2‑methoxybenzylidene)cyclohex‑
anone (1). Structure–activity relationships revealed that the mono‑carbonyl with 2,5‑dimethoxy substituted curcumi‑
noids could be an essential for the future drugs against cancer diseases.
Conclusions: Curcuminoids with diferuloyl(4‑hydroxy‑3‑methoxycinnamoyl) moiety with mono carbonyl exhibiting 
potential cytotoxic properties. The compound 14 was exhibited  (IC50 = 3.02 ± 1.20 and 1.52 ± 0.60 µg/mL) against 
MCF‑7 and MDA‑MB‑231 breast cancer cell lines.
Keywords: Curcuminoids synthesis, Breast cancer cell lines, SARs, (2E, 6E)‑2, 6‑bis(2‑ methoxybenzylidene)
cyclohexanone
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Introduction
Cancer is one of the leading causes of death worldwide, 
with approximately 14 million new cases in 2012 [1]. 
The number of new cases is expected to rise by about 
70% over the next two decades. Cancer causes of death 
globally and was responsible for 8.8 million deaths in 
2015. Globally, nearly 1 in 6 deaths is due to cancer [2]. 
In 2016, 1,685,210 new cancer cases and 595,690 can-
cer deaths are projected to occur in the United States 
[3]. Breast cancer was the commonest cancer in women 
amongst all races from the age of 20 years in Malaysia for 
2003 to 2005. According to the National Cancer Institute, 
232,340 female breast cancers and 2240 male breast can-
cers are reported in the USA. It accounts for 16% of all 
female cancers and 22.9% of invasive cancers in women 
[4–6]. Curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-
1,6-heptadiene-3,5-dione) is a natural diarylheptanoid 
extracted from the rhizome of Curcuma longa [7, 8]. 
Curcumin is a fascinating symmetrical molecules pos-
sessing interesting skeleton of β-diketone with diferu-
loyl (4-hydroxy-3-methoxycinnamic acid) moieties [9]. 
It exhibited remarkable biological activities mainly anti-
cancer [10–12], anti-inflammatory [13–15], antioxidant 
[16, 17], anti-hepatotoxic [18], nephroprotective [19], 
thrombosis suppressing [20], and hypoglycemic activities 
[21]. Curcuminoids have been identified as a potent anti-
breast cancer agent available from natural food ingredi-
ents including turmeric. This effect maybe contributed 
through targeting the estrogen receptors [22]. Advance 
understanding of bioactive metabolites through chemi-
cal synthesis has further enhanced the potential of these 
natural products including curcumin as the anticancer 
agent. For example, 4-hydroxy-3-methoxybenzylidene)-
N-methyl-4-piperidone (PAC), which is the analogue of 
curcumin were reported with enhanced antitumor effect 
against breast cancer via targeting the estrogen recep-
tor [23]. On the other hand, modification of cyclohex-
anone derivative of curcumin was reported to enhance 
cytotoxicity against estrogen receptor-negative breast 
cancer cells [24]. Although it is well known natural rem-
edies for pain still have bioavailability problems such as 
absorption, distribution, metabolism etc. [25, 26]. Due 
to its significant anti-cancer properties on the various 
cancers such as gastrointestinal, genitourinary, gyneco-
logical, hematological, pulmonary, breast, and bone dis-
eases, curcumin becomes a promising lead compound to 
develop a novel drugs [27, 28].
Results and discussion
Chemistry
Curcuminoids are the derivatives of curcumin. About 24 
curcuminoids have been synthesized and investigated 
their cytotoxic properties against various cancer lines 
and thus established the structure–activity relationship 
for the future drugs development. In our experiments, 
we have synthesized three series of mono-carbonyl ana-
logues of curcuminoids with cyclohexanone (1–10), ace-
tone (11–17) and cyclopentanone (18–24). Three series 
were synthesized by Claisen–Schmidt condensation reac-
tion by coupling the appropriate aromatic aldehydes with 
cyclohexanone, acetone and cyclopentanone by acid or 
base catalysed as previously stated by Wei [29]. In this 
project, β-diketone moiety of curcumin was modified 
with mono ketone and investigated their cytotoxic prop-
erties against Hele cell lines (human cervical cancer), 
K562 (Leukemia) cell lines, MCF-7 (an estrogen-depend-
ent) and MDA-MB-231 (an estrogen-independent) can-
cer cell lines [30]. Additionally, we are going to report 
first time the data of (2E, 6E)-2,6-bis(2-methoxyben-
zylidene)cyclohexanone (1). Recently, we have reported 
the in  vivo anti-tumour activity of 2,6-bis(4-hydroxy-
3-methoxybenzylidene)cyclohexanone (5) on 4T1 breast 
cancer cells [31]. Previously, we have published another 
curcumin derivative DK1 and naturally occurring chal-
cone flavokawain B and its derivatives on various breast 
cancer cell lines [32–34].
The compound was 1 purified as yellow liquid. The 
UV spectrum of compound 1 showed the absorption 
wavelength, λmax at 339  nm corresponding to the α,β 
conjugated carbonyl group (C=O) compound. The IR 
absorption bands at 1636  cm−1 corresponding to car-
bonyl (C=O) and 2942–3001  cm−1 referred to aro-
matic C–H stretching functional groups. The 1H NMR 
spectrum (600  MHz,  CDCl3) of compound 1 appeared 
at δ 1.75 as multiplet (2H) was assigned to the methyl-
ene proton  (CH2) at C4. A methylene protons at 2.84 as 
a multiplet (4H) integrated was corresponding to the 
C3 and C5 atoms. A singlet appeared at 3.86 integrated 
by 6H was assigned to the methoxy protons  (OCH3) 
at C2′ and C2″ position. A multiplet appeared at 6.92 
was assigned to the aromatic protons at C3′ and C3″ 
methine protons. Two protons (2H) integrated at 6.96 
shown a multiplet were assigned to the C5′ and C5″ 
protons. Another multiplet appeared at 7.33–730 (4H) 
was assigned to the C4′, C4″, C6′ and C6″ as aromatic 
methine protons. A broad singlet appeared at 7.98 inte-
grated by 2H was due to the olefinic protons (–C=C–H). 
The board band decoupled spectra 13C NMR showed 
the presence seven quaternary carbons, three methylene 
and ten methine carbons atoms. The compound showed 
EI-MS molecular mass was at m/z 334. The molecu-
lar formula of compound 1 was supported by HREI-
MS calculated  C22H22O3 334.1575, found for 334.1580, 
which supported the proposed structure of compound 
1 (Fig. 1). Previously, the radical scavenger and enzyme 
inducer activity of compound 1 obtained from Aldrich 
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was reported by Dinkova-Kostavo et  al. [35]. Interest-
ingly, the data of all the compounds were character-
ized precisely on 600  MHz Bruker and 500  MHz and 
assignments were made carefully. The data of known 
compounds were compared with the previously pub-
lished by Wei, Hosoya and Du [29, 36, 37].
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Fig. 1 Chemical structures of curcuminoids (1–24) and curcumin
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Structure–activity relationship
All the curcuminoids have been screened against HeLa, 
K562, MCF-7 and MDA-MB-231 cancer cell lines and 
results are depicted in Table 1. Among the cyclohexanone 
series 1–10, compound 4 was the most potent cytotoxic 
against four cancer lines especially breast can cell lines 
exhibited  (IC50 = 11.04 ± 2.80, 6.50 ± 01.80, 8.70 ± 3.10 
and 2.30 ± 1.60  µg/mL), respectively. Compound 5 
possess the partial structure of curcumin showed 
 (IC50 = 6.03 ± 1.70 and 3.03 ± 1.00 µg/mL) against MCF-7 
and MDA-MB-231 breast cancer cell lines almost three 
to four times more active than curcumin (Table 1). Oth-
ers curcuminoids 1, 3, 6, 7, 8, 10 also showing good 
cytotoxicity against breast cancer lines MCF-7 and MDA-
MB-231 and moderated against HeLa and K562 cell 
lines. Curcuminoids with acetone series 11–17 exhib-
ited more potential cytotoxic effects on four type can-
cers cell lines, which is comparable with curcumin  IC50 
values in Table 1. Among acetone series, the compound 
14 was found to be the most cytotoxic in breast cancer 
lines MCF-7 and MDA-MB-231 and moderate against 
HeLa and K562 cell lines. Compound 11 also exhibited 
 (IC50 = 11.31 ± 1.33, 4.50 ± 1.20 and 2.07 ± 1.75  µg/mL) 
against HeLa, MCF-7 and MDA-MB-231, respectively. 
Other curcuminoids 15, 16, and 17 possessing Cl, Br 
and F substituted showing moderate cytotoxicity against 
four cancer lines (Table 1). Compound 17 with trimeth-
oxy substituted also exhibiting potential cytotoxicity 
with  (IC50 = 2.50 ± 1.10 and 3.10 ± 1.06  µg/mL) against 
breast cancer lines MCF-7 and MDA-MB-231, which is 
compatible with the previously published by Fuchs [38]. 
Curcuminoids 18–24 with cyclopentanone series did not 
show any significant cytotoxicity against all types of can-
cer lines except compound 22, showing better cytotoxic 
effects against Hela and MCF-7 and MDA-MB-231 can-
cer then curcumin. The lower cytotoxicity of compounds 
18–24 possibly due to the ring strain, which could be 
sterically not well-fitted with the estrogen receptors. 
Cytotoxic results of curcuminoids with acetone series 
1–10 and methoxy substituted exhibiting selectively 
more potential than cyclohexanone (11–17) and cyclo-
pentanone (18–24) series. The results are summarized in 
Table 1.
Most of curcuminoids are potent as compared to the 
curcumin with  (IC50 = 22.50 ± 5.50 and 26.50 ± 1.40  µg/
mL) against MCF-7 and MDA-MB-231 (Table 1). Several 
reports on curcuminoids with mono-carbonyl (acetone 
series) have been even better pharmacological properties 
than curcumin [22, 38]. Due to enolization and chelat-
ing (hydrogen bonding with the diketone), curcumin 
exhibited slightly lower cytotoxic effect than the modi-
fied derivatives. This could be due to the weak binding 
with the receptors, thus cause the weak pharmacokinetic 
profiles [39]. All curcuminoids possessed bis-enone con-
jugated system, which is quite reasonable site to binding 
with the Michael receptor selectivity with target nucleo-
phile [30, 40–42]. The curcuminoids with mono-carbonyl 
1–10 could be potential analogues for the drug discov-
ery against cancer. In this respect, curcumin derivatives 
bearing a mono-carbonyl and methoxy groups especially 
cyclohexanone (1–10) and acetone 11–17 series could be 
a remarkable approach for the improvement of bioavail-
ability problems related to curcumin [43, 44].
X‑ray structure description
Crystal data of compound 4 was given in Table  2. One 
crystal structure was determined by using X-ray diffrac-
tion method. Figure 2 showed the molecular structure of 
compound 4. Compound 4 crystalized in orthorhombic 
crystal system, space group Pna21.
Table 1 IC50 values of curcuminoids against HeLa, K562, 
MCF-7 and MBA-MB-231
Data are expressed in terms of ± SE of three independent experiments
Compounds HeLa K562 MCF‑7 MDA‑MB‑231
IC50 (µg/mL)
1 9.21 ± 1.20 16.04 ± 1.30 3.46 ± 1.22 3.01 ± 0.60
2 38.03 ± 3.10 30.12 ± 3.30 42.00 ± 4.20 65.00 ± 4.10
3 12.50 ± 1.30 22.50 ± 3.20 8.50 ± 1.50 9.50 ± 1.40
4 11.04 ± 2.80 6.50 ± 01.80 8.70 ± 3.10 2.30 ± 1.60
5 > 30 17.50 ± 0.50 6.03 ± 1.70 3.03 ± 1.00
6 15.07 ± 1.60 20.04 ± 1.10 > 30 > 30
7 12.00 ± 1.60 22.50 ± 1.10 10.50 ± 2.10 7.401 ± 1.10
8 > 30 > 30 6.50 ± 2.70 3.02 ± 1.10
9 11.01 ± 2.10 55.02 ± 3.40 10.50 ± 1.80 6.30 ± 1.30
10 > 30 > 30 14.02 ± 1.80 11.90 ± 3.10
11 11.31 ± 1.33 15.03 ± 1.90 4.50 ± 1.20 2.07 ± 1.75
12 12.01 ± 1.10 32.50 ± 2.10 20.50 ± 2.50 11.00 ± 2.10
13 15.20 ± 1.20 > 30 10.00 ± 2.10 9.50 ± 1.10
14 14.03 ± 1.40 > 30 3.02 ± 1.20 1.52 ± 0.60
15 > 30 15.01 ± 1.30 7.50 ± 1.10 9.20 ± 0.80
16 11.00 ± 1.20 12.50 ± 0.95 25.00 ± 3.20 14.21 ± 2.10
17 6.15 ± 1.20 > 30 2.50 ± 1.10 3.10 ± 1.06
18 > 30 > 30 > 30 18.13 ± 6.10
19 > 30 > 30 > 30 > 30
20 > 30 > 30 > 30 > 30
21 > 30 > 30 > 30 27.50 ± 4.40
22 9.00 ± 1.60 > 30 12.50 ± 2.10 6.40 ± 1.10
23 > 30 > 30 > 30 > 30
24 > 30 > 30 > 30 > 30
Curcumin > 30 > 30 22.50 ± 5.50 26.50 ± 1.40
Doxorubicin 4.01 ± 1.20 1.23 ± 1.10 2.50 ± 1.10 0.60 ± 1.10
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Experimental
Chemistry
General
Melting points were determined on Electrothermal IA 
9100 capillary melting point apparatus and are uncor-
rected. UV spectra were recorded on UV–Vis spectro-
photometer model type of Genesys 10 s and expressed in 
nm. Thermo Scientific. Glass cuvettes were used. All the 
samples were dissolve in chloroform or methanol. FT-IR 
spectroscopic studies were carried out on FTIR spectro-
photometer 1000 model Perkin Elmer at room tempera-
ture 25  °C. KBr pellets were dried in oven and scanned 
for calibration purpose. 1H NMR spectra of compounds 
were recorded on a Bruker Ascend TM 600  MHz 
machine, while the spectra of compounds 12, 16, 17 were 
recorded on 500 MHz NMR spectrometers. The chemical 
shifts (δ) are presented with references to  CDCl3 (δ: 7.25) 
and TMS (δ: 0.00) as the internal reference. Electron-
spray ionization mass spectra in positive mode (ESI–MS) 
were recorded on a Bruker Esquire 3000 spectrometer. 
Column chromatography purifications were carried out 
on Silica Gel 60 (Merck, 70–230 mesh, ASTM) and flash 
silica gel (230–400 mesh, ASTM, Merck). The purity of 
all compounds were checked by thin-layer chromatogra-
phy (TLC) and 1H-NMR spectra. All reagents used were 
of analytical grade. All the chemicals were purchased 
from Aldrich, U.S.A. Other reagents were purchased 
from Sinopharm Chemical Reagent Co. Ltd., China.
Table 2 Crystal data and parameters for structure refine-
ment of 4
Crystal data 4
CCDC 1548735
Chemical formula C24H26O5
Mr 394.45
Crystal system, space group Orthorhombic, Pna21
Temperature (K) 296
a, b, c (Å) 8.529 (8), 25.65 (2), 9.430 (8)
α, β, γ (°) 90, 90, 90
V (Å3) 2063 (3)
Z 4
Radiation type Mo Kα
µ (mm−1) 0.09
Crystal size (mm) 0.47 × 0.24 × 0.05
Data collection
 Diffractometer Bruker APEXII DUO CCD area‑
detector diffractometer
 Absorption correction Multi‑scan (SADABS; Bruker, 2009)
 Tmin, Tmax 0.8434, 0.9624
 No. of measured, independent and 
observed [I> 2σ(I)] reflections
17,650, 3611, 1468
 Rint 0.145
 (sin θ/λ)max (Å
−1) 0.594
Refinement
 R
[
F
2 > 2σ
(
F
2
)]
, wR(F2), S 0.071, 0.184, 1.00
 No. of reflections 3611
 No. of parameters 266
 H‑atom treatment H‑atom parameters constrained
 Δρmax, Δρmin (e Å
−3) 0.12, − 0.14
Fig. 2 Molecular structures of compound 4 showing the atomic numbering scheme
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Synthetic procedures
Method A (acid‑catalyzed)
A typical Claisen-Schmidt condensation reaction proce-
dure was used to prepare all curuminoids. Appropriate 
mono ketone (cyclohexanone, acetone and cyclopen-
tanone) 10 mol (1 equiv) was dissolved in absolute eth-
anol (15–20  mL). Substituted benzaldehydes 20  mol, (2 
equiv) was added slowly. About 1–2  mL concentrated 
HCl was added drop wise over 5–10  min in a stirred 
mixture of ketone. The reaction mixture was stirred 
overnight (12–24  h). The product was monitored by 
comparing the Co-TLC with the starting material. The 
products were extracted with ethyl acetate by dissolving 
the compounds in distilled water (100  mL). Curcumi-
noids were purified by silica gel column chromatography 
(ethyl acetate/hexane) and re-crystallized with hot solu-
tion of ethyl acetate and ethanol.
Method B (base‑catalyzed)
The general procedure Claisen–Schmidt condensation 
reaction was used to synthesize curcuminoids by using 
this method involved in addition of certain amount of 
mono ketone (cyclohexanone, acetone and cyclopen-
tanone) to a solution of substituted aldehydes in MeOH 
or  C2H5OH by adding KOH or NaOH. The reaction 
mixture is stirred at room temperature and monitored 
by TLC. The products are extracted and purified as 
described as in acid catalysed [43, 44].
(2E,6E)‑2,6‑bis(2‑Methoxybenzylidene)cyclohexanone 
(1) Yellow liquid; yield (86%); UV–Vis  (CHCl3) λmax: 
302, 339  nm; IR (KBr,) v 3023 (Ar C–H stretch), 1636 
(C=O), 1527 (Ar C=C<)  cm−1; 1H NMR  (CDCl3, 
600 MHz) δ 1.75 (m, 2H, 4-H), 2.84 (m, 4H, 3, 5-H), 3.86 
(s, 6H,  OCH3, C-2′ & C-2″), 6.92 (m, 2H, 3′, 3″-H), 6.96 
(m, 2H, 5′, 5″-H), 7.32 (m, 2H, 4′, 4″-H), 7.33–7.30 (m, 
4H, 4′, 4″, 6′, 6″-H), 7.98 (brs, 2H, –C=C–H). 13C NMR 
 (CDCl3, 150  MHz) δ 23.5 (C-4), 28.6 (C-3, C-5), 55.5 
 (OCH3), 110.6 (C-3′, C-3″), 119.9 (C-5′, C-5″), 125.2 
(C-4′, C-4″, C-6′, C-6″), 130.3 (C-1′, C-1″), 132.5 (C-2, 
C-6), 136.6 (–C=C–H), 158.4 (C-2′, C-2″), 190.6 (C=O); 
EI-MS m/z 334.0 (10), 303.1 (20), 240.3 (14), 161.2 (19), 
107.4 (23), 77.0 (64); HREI-MS for  C22H22O3  M+, calcd.: 
m/z 334.1575, found: m/z 334.1589.
(2E,6E)‑2,6‑bis(4‑Methoxybenzylidene)cyclohexanone 
(2) Yellow crystals; yield (74%); m.p. 152–153  °C (lit. 
[29] 148–149  °C); UV–Vis  (CHCl3) λmax: 362  nm; IR 
(KBr) v 3010 (Ar C–H stretch), 1660 (C=O), 1508–1594 
(Ar C=C)  cm−1; 1H NMR  (CDCl3, 600 MHz) δ 1.80 (m, 
2H, 4-H), 2.92 (m, 4H, 3, 5-H), 3.84 (s, 6H,  OCH3, C-4′, 
4″), 6.93 (d, 4H, 3′, 3″, 5′, 5″-H, J = 6.78 Hz), 7.45 (d, 4H, 
2′, 2″, 6′, 6″-H, J = 6.78  Hz), 7.76 (brs, 2H, –C=C–H); 
EI-MS m/z 334.0 (100), 303.45 (36), 240.1 (23), 161.2 
(10), 107.0 (28); HREI-MS for  C22H22O3  M+, calcd.: m/z 
334.1568, found: m/z 334.1573.
(2E,6E)‑2,6‑bis(2,3‑Dimethoxybenzylidene)cyclohex‑
anone (3) Yellow crystals; yield (92%); m.p. 105–106 °C 
(lit. [36] 107–109 °C); UV–Vis  (CHCl3) λmax: 324 nm; IR 
(KBr) v 3023 (Ar C–H stretch), 1622 (C=O), 1536–1536 
(Ar C=C)  cm−1; 1H NMR  (CDCl3, 600 MHz) δ 1.75 (m, 
2H, 4-H), 2.80 (m, 4H, 3, 5-H), 3.82 (s, 6H,  OCH3, C3′, 
3″), 3.88 (s, 6H,  OCH3, C-2′, 2″), 6.93 (m, 4H, 4′, 4″, 6′, 
6″-H), 7.06 (brt, 2H, 5′, 5″-H, J = 7.98 Hz), 7.94 (brs, 2H, 
–C=C–H); 13C NMR, (150  MHz,  CDCI3) δ 23.3 (C-4), 
28.78 (C-3, C-5), 55.9  (OCH3), 61.2  (OCH3), 112.8 (C-5′, 
C-5″), 122.2 (C-4′, C-4″), 123.5 (C-6′, C-6″), 130.5 (C-1′, 
C-1″), 132.5 (C-2, C-6), 137.5 (C=C–H), 152.9 (C-2′, 
C-2″, C-3′, C-3″), 190.4 (C=O); EI-MS m/z 394 (5), 363.0 
(100), 331.2 (68), 161.23 (86), 227.33 (24), 136.18 (29); 
HREI-MS for  C24H26O5  M+, calcd.: m/z 394.1783, found: 
m/z 394.1778.
(2E,6E)‑2,6‑bis(4‑Hydroxy‑3‑methoxybenzylidene)
cyclohexanone (5) Synthesis, purification and experi-
mental data of compound 5 was recently published by us 
[31].
(2E,6E)‑2,6‑bis(2‑Chlorobenzylidene)cyclohexanone 
(6) Yellow crystals; yield (68%); m.p. 109–110  °C (lit. 
[36] 94–95 °C); UV–Vis  (CHCl3) λmax: 320 nm; IR (KBr) 
v 3073 (Ar C–H stretch), 1663 (C=O), 1574–1433 (Ar 
C=C)  cm−1; 1H NMR  (CDCl3, 600 MHz) δ 1.76 (m, 2H, 
4-H), 2.78 (m, 4H, 3, 5-H), 7.33 (m, 2H, 3′, 3″-H), 7.28 
(m, 4H, 4′, 4″, 5′, 5″-H), 7.44 (m, 2H, 6′, 6″-H), 7.91 (brs, 
2H, –C=C–H); EI-MS m/z 343.0 (5), 307 (100), 272 (8), 
166 (4), 138 (6), 112 (17); HREI-MS for  C20H16Cl2O  M+, 
calcd.: m/z 342.0578, found: m/z 342.0572.
(2E,6E)‑2,6‑bis(4‑Chlorobenzylidene)cyclohexanone 
(7) Yellow crystals; yield (86%); m.p. 149–153  °C (lit. 
[29] 147–149  °C); UV–Vis  (CHCl3) λmax: 335  nm; IR 
(KBr) v 3063 (Ar C–H stretch), 1604 (C=O), 1576–1487 
(Ar C=C)  cm−1; 1H NMR  (CDCI3, 500 MHz) δ 1.80 (m, 
2H, 4-H), 2.89 (m, 4H, 3, 5-H), 7.34 (m, 2H, 2′, 2″-H), 7.34 
(m, 2H, 3′, 3″-H), 7.34 (m, 2H, 5′, 5″-H), 7.34 (m, 2H, 6′, 
6″-H), 7.73 (brs, 2H, –C=C–H); EI-MS m/z 343 (76), 307 
(87), 272 (71), 244 (31), 166 (14), 138 (22), 112 (9); HREI-
MS for  C20H16Cl2O  M+, calcd.: m/z 342.0678, found: m/z 
342.0672.
(2E,6E)‑2,6‑bis(3,4‑Dimethoxybenzylidene)cyclohexanone 
(10) Yellow crystals; yield (74%); m.p. 146–149  °C (lit. 
[37] 148–150  °C); UV–Vis  (CHCl3) λmax: 373  nm; IR 
(KBr) v 3036 (Ar C–H stretch), 1614 (C=O), 1489–1462 
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(Ar C=C)  cm−1; 1H NMR  (CDCl3, 600 MHz) δ 1.83 (m, 
2H, 4-H), 2.95 (m, 4H, 3, 5-H), 3.90 (s, 6H,  OCH3, C-3′, 
3″), 3.92 (s, 6H,  OCH3, C-4′, 4″), 6.91 (d, 2H, 5′, 5″-H, 
J = 8.34 Hz), 7.02 (d, 2H, 2′, 2″-H, J = 1.92 Hz), 7.12 (dd, 
2H, 6′, 6″-H, J = 8.34, 1.92 Hz), 7.76 (brs, 2H, –C=C–H); 
EI-MS m/z 394 (3), 363 (100), 331 (9), 161 (4), 227 (23), 
136 (3), 77 (31); HREI-MS for  C24H26O5  M+, calcd.: m/z 
394.1784, found: m/z 394.1787.
(1E,4E)‑1,5‑bis(2‑Methoxyphenyl)‑penta‑1,4‑dien‑3‑one 
(11) Yellow crystals; yield (66%); m.p. 111–114  °C (lit. 
[45] 118–120 °C); UV–Vis  (CHCl3)λmax: 312, 360 nm; IR 
(KBr) v 3023 (Ar C–H stretch), 1614 (C=O), 1489–1462 
(Ar C=C)  cm−1; 1H NMR  (CDCl3, 600  MHz) δ 3.90 (s, 
6H,  OCH3, C-2′, 2″), 6.93 (d, 2H, 3′, 3″-H, J = 8.34  Hz), 
6.99 (t, 2H, 4′, 4″-H, J = 8.46, 7.4 Hz), 7.18 (d, 2H, 2, 4-H, 
J = 16.08 Hz), 7.36 (td, 2H, 5′, 5″-H, J = 7.4, 1.6 Hz), 7.62 
(dd, 2H, 6′, 6″-H, J = 7.6, 1.6  Hz), 8.08 (d, 2H, 1, 5-H, 
J = 16.08 Hz); EI-MS m/z 294 (100), 263 (8), 234 (15), 186 
(50), 161 (36), 133 (33), 77 (16); HREI-MS for  C19H18O3 
 M+, calcd.: m/z 294.1255, found: m/z 294.1251.
(1E,4E)‑1,5‑bis(4‑Methoxyphenyl)‑penta‑1,4‑dien‑3‑one 
(12) Yellow crystals; yield (79%); m.p. 121–122  °C (lit. 
[46] 119–120 °C); UV–Vis  (CHCl3) λmax: 354 nm; IR (KBr) 
v 3033 (Ar C–H stretch), 1624 (C=O), 1590–1488 (Ar 
C=C)  cm−1. 1H NMR  (CDCl3, 500 MHz) δ 3.87 (s, 6H, 
 OCH3, C-4′, 4″), 6.94 (d, 4H, 3′, 3″, 5′, 5″-H, J = 8.75 Hz), 
6.99 (d, 2H, 2, 4-H, J = 16.0  Hz), 7.60 (d, 4H, 2′, 2″, 6′, 
6″-H, J = 8.75 Hz), 7.74 (d, 2H, 1, 5-H, J = 16.0 Hz); EI-MS 
m/z 294.14 (100), 263 (15), 234 (20), 186 (54), 161 (38), 
133 (36), 77 (21); HREI-MS for  C19H18O3  M+, calcd.: m/z 
294.1264, found: m/z 294.1257.
(1E,4E)‑1,5‑bis(2,3‑Dimethoxyphenyl)‑penta‑1,4‑dien‑
3‑one (13) Yellow solid; yield (68%); m.p. 103–104  °C 
(lit. [36] 106–108  °C); UV–Vis  (CHCl3) λmax: 330  nm; 
IR (KBr) v 3011–2943 (Ar C–H stretch), 1619 (C=O), 
1577–1479 (Ar C=C)  cm−1; 1H NMR  (CDCl3, 600 MHz) 
δ 3.87 (s, 12H,  OCH3, C-2′, 2″, 3′, 3″), 6.97 (dd, 2H, 4′, 
4″-H, J = 8.16, 1.44  Hz), 7.10 (t, 2H, 5′, 5″-H, J = 8.04, 
8.00 Hz), 7.16 (d, 2H, 2, 4-H, J = 16.1 Hz), 7.26 (dd, 2H, 6′, 
6″-H, J = 8.00, 1.44 Hz), 8.04 (d, 2H, 1, 5-H, J = 16.1 Hz); 
EI-MS m/z 354 (5), 323 (3), 230 (4), 186 (9), 132 (13), 191 
(4), 163 (7), 77 (52); HREI-MS for  C21H22O5  M+, calcd.: 
m/z 354.1467, found: m/z 394.1462.
(1E,4E)‑1,5‑bis(4‑Chlorophenyl)‑penta‑1,4‑dien‑3‑one 
(16) Yellow solid; yield (72%); m.p. 193–195 °C (lit. [36] 
192–193  °C); UV–Vis  (CHCl3) λmax: 333  nm; IR (KBr) 
v 3065 (Ar C–H stretch), 1608 (C=O), 1584–1489 (Ar 
C=C str.)  cm−1; 1H-NMR  (CDCl3, 500  MHz) δ 7.04 (d, 
2H, 2, 4-H, J = 15.9  Hz), 7.40 (dd, 4H, 3′, 3″, 5′, 5″-H, 
J = 8.60 Hz), 7.56 (d, 4H, 2′, 2″, 6′, 6″-H, J = 8.60 Hz), 7.70 
(d, H, 1, 5-H, J = 15.9 Hz); 13C NMR (150 MHz,  CDCl3) 
δ 126.0 (C-2, 4), 128.7 (C-3′, 3″), 128.7 (C-5′, 5″), 129.3 
(C-2′, 2″), 129.3 (C-6′, 6″), 133.3 (C-1′, 1″), 136.5 (C-4′, 
4″), 142.1 (C-1, 5), 188.3 (C=O); EI-MS m/z 302 (60), 267 
(32), 232 (5), 203 (20), 165 (35), 137 (49), 77 (5); HREI-
MS for  C17H12Cl2O  M+, calcd.: m/z 302.0265, found: m/z 
302.0259.
(1E,4E)‑1,5‑bis(2,4,6‑Trimethoxyphenyl)‑penta‑1,4‑dien
‑3‑one (17) Yellow solid; yield (68%); m.p. 213–215  °C 
(lit. [36] 209–211 °C); UV–Vis  (CHCl3) λmax: 381 nm. IR 
(KBr) 3002 (Ar C–H str.), 1629 (C=O), 1561–1466 (Ar 
C=C)  cm−1; 1H NMR  (CDCl3, 600 MHz) δ 3.74 (s, 6H, 
2 × OCH3, C-4′, 4″), 3.85 (s, 12H, 4 ×  OCH3, C-2′, 2″, 
6′, 6″), 6.13 (brs, 4H, 3′, 3″, 5′, 5″-H), 7.46 (d, 2H, 2, 4-H, 
J = 16.30  Hz), 8.12 (d, 2H, 1, 5-H, J = 16.30  Hz); EI-MS 
m/z 414 (5), 131 (6), 105 (10); HREI-MS for  C23H26O7 
 M+, calcd.: m/z 414.1671, found: m/z 414.1679.
(2E,5E)‑2,5‑bis(4‑Methoxybenzylidene)cyclopentanone 
(19) Yellow solid; yield (66%); m.p. 150–155.5  °C (lit. 
[29] 158–161  °C); UV–Vis  (CHCl3) λmax: 391  nm; IR 
(KBr) v 2964 (Ar C–H stretch), 1696 (C=O), 1597–1509 
(Ar C=C)  cm−1; 1H NMR  (CDCI3, 600  MHz) δ 3.09 
(brs, 4H, 3, 4-H), 3.86 (s, 6H, 2 ×  OCH3, C-4′, 4″), 6.98 
(brd, 2H, 5′, 5″-H, J = 8.34  Hz), 6.98 (brd, 2H, 3′, 3″-H, 
J = 8.34  Hz), 7.57 (brt, 2H, 2′, 2″-H, J = 8.52  Hz), 7.57 
(brt, 2H, 6′, 6″-H, J = 8.52 Hz), 7.58 (brs, 2H, –C=C–H); 
EI-MS m/z 320 (11), 213 (8), 183 (5), 131 (12), 77 (16); 
HREI-MS for  C21H20O3  M+, calcd.: m/z 320.1412, found: 
m/z 320.140.
(2E,5E)‑2,5‑bis(2,3‑Dimethoxybenzylidene)cyclopen‑
tanone (20) Yellow solid; yield (54%); m.p. 156–158  °C 
(lit. [36] 155–157 °C); UV–Vis  (CHCl3) λmax: 346 nm; IR 
(KBr) v 3032 (Ar C-H stretch), 1694 (C=C), 1622 (C=O), 
1584–1489 (Ar C=C)  cm−1; 1H NMR  (CDCI3, 600 MHz) 
δ 3.02 (brs, 4H, 3, 4-H), 3.87 (s, 6H,  OCH3, C-2′, 2″), 3.88 
(s, 6H,  OCH3, C-3′, 3″), 6.96 (m, 2H, 4′, 4″-H), 7.10 (t, 2H, 
5′, 5″-H, J = 7.9  Hz), 7.16 (dd, 2H, 6′, 6″-H, J = 7.9  Hz), 
7.93 (brs, 2H, –C=C–H); EI-MS m/z 380 (3), 349 (4), 163 
(10), 137 (10), 98 (18); HREI-MS for  C23H24O5  M+, calcd.: 
m/z 380.1618, found: m/z 380.1623.
(2E,5E)‑2,5‑bis(4‑Hydroxy‑3‑methoxybenzylidene)cyclo‑
pentanone (22) Yellow solid; yield (58%); m.p. 212–
214  °C (lit. [47] 214  °C); UV–Vis  (CHCl3) λmax: 388 nm; 
IR (KBr) v 3043 (Ar C–H stretch), 1690 (C=C), 1620 
(C=O), 1588–1485 (Ar C=C)  cm−1; 1H NMR  (CDCl3, 
500 MHz) δ 3.03 (s, 4H, 3, 4-H), 3.88 (s, 6H,  OCH3, C-3′, 
3″), 6.92 (d, 2H, 5′, 5″-H, J = 8.30  Hz), 7.04 (brs, 2H, 2′, 
2″-H), 7.14 (dd, 2H, 5′, 5″-H, J = 8.30, 1.65 Hz), 7.46 (brs, 
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2H, –C=C–H); EI-MS m/z 352; HREI-MS for  C21H20O5 
 M+, calcd.: m/z 352.1310, found: m/z 352.1305.
(2E,5E)‑2,5‑bis(3,4‑Dimethoxybenzylidene)cyclopen‑
tanone (23) Yellow solid; yield (54%); m.p. 191–193  °C 
(lit. [37] 188–190 °C); UV–Vis  (CHCl3) λmax: 368 nm; IR 
(KBr) v 3006 (Ar C–H stretch), 1693 (C=O), 1592–1515 
(Ar C=C)  cm−1; 1H NMR  (CDCl3, 600 MHz) δ 3.12 (brs, 
4H, 3, 4-H), 3.94, 3.93 (s, 12H, 4 ×  OCH3, C-3′, 3″, 4′, 
4″), 6.96 (d, 2H, 5′, 5″-H, J = 8.34  Hz), 7.14 (s, 2H, 2′, 
2″-H), 7.24 (dd, 2H, 6′, 6″-H, J = 8.34 Hz), 7.55 (brs, 2H, 
–C=C–H); 13C NMR (150 MHz,  CDCl3) δ 26.3 (C-3, 4), 
56.0 (C–O), 111.2 (C-2′, 2″), 113.5 (C-5′, 5″), 124.6 (C-6′, 
6″), 129.0 (C-1′, 1″), 133.7 (–C=C–H), 148.9 (C-2, 5), 
150.3 (C-3′, 3″), 150.3 (C-4′, 4″), 196.0 (C=O); EI-MS m/z 
380.1 (5), 191.0 (10), 132.2 (18), 77.2 (55); HREI-MS for 
 C23H24O5  M+, calcd.: m/z 380.1624, found: m/z 380.1619.
Anticancer activity
Sample preparation
Stock samples at 1 mg/mL of dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich, USA) were prepared and keep at 4 °C.
MTT cell viability assay
Breast cancer MCF-7 and MDA-MB-231 cells, chronic 
myelogenous leukemia K562 cells, and cervical cancer 
HeLa cells lines were purchased from American Type 
Culture Collection (ATCC, USA) and cultured at 37  °C, 
5%  CO2 and 90% humidity using RPMI-1640 medium 
(Sigma-Aldrich, USA) supplemented with 10% Foetal 
Bovine Serum (FBS) (Thermo Fisher Scientific, USA). 
For MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetra-
zolium bromide) cell viability assay [48], MCF-7, MDA-
MB-231, K562 and HeLa cells were seeded overnight in 
96-well plates at 8 ×  104 cells/well at 37 °C of  CO2 [49]. 
Then, 100 µL of media was discarded for all well-plates 
and compounds were serially diluted into the seeded cells 
at the concentration ranging between 30–0.47  µg/mL 
with cells treated with 3% DMSO (Sigma-Aldrich, USA) 
as the negative control. All samples were tested for tripli-
cates. After 72 h of incubation, all well was added with 20 
µL of MTT solution (5 mg/mL) and further incubated for 
3 h. At that point, 170 µL of solution were discarded and 
100 µL of DMSO (Sigma-Aldrich, USA) was added to all 
wells. Finally, absorbance was recorded by ELISA plate 
reader (Biotek-Instruments, USA) at the wavelength of 
570 nm. Percentage of cell viability was calculated using 
following formula [38, 39]. The assay was performed in 
triplicate to calculate the half maximal inhibitory concen-
tration  (IC50) values. Doxorubicin was used as a positive 
control.
Cell viability (%) = [OD sample at 570 nm/OD negative 
control at 570 nm] × 100%
IC50 value (concentration of compounds inhibited 50% 
of cell viability) was determined from the graph of cell 
viability vs absorbance.
X‑ray crystallographic analysis
X-ray analysis for all these samples were performed using 
Bruker APEX II DUO CCD diffractometer, employing 
MoKα radiation (λ = 0.71073 Å) with φ and ω scans, at 
room temperature. Data reduction and absorption cor-
rection were performed using SAINT and SADABS 
programs [50–53]. The structures of compound 4 was 
solved by direct methods and refined by full-matrix 
least-squares techniques on F2 using SHELXTL software 
package. Crystallographic data of the reported structures 
have been deposited at the Cambridge Crystallographic 
Data Centre with CCDC deposition numbers of 1548735. 
Copy of available material can be obtained free of charge, 
on application to CCDC, 12 Union Road, Cambridge CB2 
1EZ, UK, (Fax: +44-(0)1223-336033 or e-mail: deposit@
ccdc.cam.ac.uk).
Conclusions
In conclusion, we have examined three series of cur-
cumin analogues against four types (HeLa, K562, MCF-7 
and MDA-MB-231) cancer cell lines. Curcuminoids with 
diferuloyl (4-hydroxy-3-methoxycinnamoyl) moiety with 
mono carbonyl exhibiting potential cytotoxic properties. 
The compound 14 was exhibited  (IC50 = 3.02 ± 1.20 and 
1.52 ± 0.60  µg/mL) against MCF-7 and MDA-MB-231 
breast cancer cell lines. Structure activity relationship 
revealed that the role of methoxy groups are important. 
Curcumin derivatives, 4, 5, 9, 14, 11 and 17 exhibited 
significant cytotoxic activity (Table  1). Curcuminoids 
with acetone series such as 2,5-dimethoxy substituted 
with mono ketones were found to be more selective and 
potential cytotoxic agents, which could be the best tem-
plet for future drug discovery against selective cancer 
especially breast cancer lines.
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